Current Events

The main objective of “Ars Separatoria 2008” is to present and discuss the latest achievements in separation, isolation, purification methods and processes applied in chemistry, industry and environmental protection. The topics of Symposium: membrane separation techniques, phase equilibria, extraction, flotation, chromatography

1. Advanced methods of synthesis and preparation of polymer colloid; novel polymerization procedures, living radical-mediated heterogeneous polymerizations (RAFT, ATRP, etc.); micro and nano-encapsulation processes, polymer/inorganic nanocomposite particles, core-shell microspheres, hollow particles. 2. Nano and microparticles, polymer micelles and vesicles for life sciences, drug delivery and biomedical diagnostics, polyelectrolyte/DNA complexes for gene delivery. Biocompatible/biodegradable particles, dendrimers. Micro and nano technologies in biomedicine. 3. Stimuli-responsive polymer colloids, such as temperature-, pH-, light-sensitive, magnetic and conducting polymer particles, non-spherical particles; characterization of particle surfaces and morphology by various techniques, including electron microscopy, chromatography, light scattering, etc. 4. New trends in industrial applications of polymer colloids in coatings, composite materials, adhesives, paper and textile, etc. Colloidal crystals for optical devices.

The annual Analytical Research Forum (ARF) is the premier Analytical Science meeting of the RSC and will be held this year at the University of Hull. The meeting is primarily for early-stage analytical science researchers (industrial scientists, PhD students and postdoctoral fellows) to present their latest results in the context of the wider analytical science community. The programme, which features both poster sessions and lectures, will include oral presentations from students, medal winners and international leaders in the field. Following the success of the 2007 meeting, we expect this meeting to be attended by around 200 delegates.

The Ninth Tetrahedron Symposium will provide a comprehensive review of the state of current research and, more importantly, the challenges to future discovery. Coverage includes: Organic Synthesis, Bioorganic Chemistry, Medicinal Chemistry, Computational Chemistry, Molecular Recognition, Organic Chemistry of Materials.

Cells are potential solutions! Cambridge Healthtech Institute's Third Annual CELLutions SUMMIT is uniquely designed to explore the evolving field of next-generation cells, engineered 3D cellular models, and therapeutic cellular-in-human use. Scientific technological progress brings fundamental understanding and provides the foundation for more rapid advances toward the clinic. Targeted Topics: • Cell Sources • 3D Cellular Models • Cell Therapies • Five @ Five www.CELLutionsSUMMIT.com

• Novel Vaccines: Bridging Research, Development & Production • Advances in Cancer Vaccines • Clinical Risk Management & Safety for Vaccines www.TargetedImvacS.com

The 236th ACS National Meeting & Exposition will take place August 17-21, 2008 in Philadelphia, Pennsylvania. Events will be held at the Pennsylvania Convention Center and hotels around the city. The technical program will feature original programming hosted by 31 technical divisions, one secretariat, three committees, and the ACS president and will include thematic programming around "Chemistry for Health: Catalyzing Translational Research."

At this year ’s Systems Integration in Biodefense meeting, we will hear from industry leaders about their strategy for meeting the needs of the community and bridging the technology gaps that still exist. New assays will be introduced that are highly multiplexed, integrated and field deployable. Technology developments in sample prep, signal transduction and amplification will be showcased, and specific examples of creating an integrated system will be presented. Dual-use application is an essential feature for products to have utility in biodefense and clinical settings. A discussion on getting products to market and facing commercialization, collaboration, and business challenges will be addressed. The meeting will be followed by the 2nd Annual Enabling Point-of-Care Diagnostics to elucidate the transition from biodefense to a clinical setting, and the tactical issues of implementation. www.healthtech.com

The POC diagnostics industry is rapidly expanding, and promises to answer the need for more integrated and immediate clinical results. Technologies are being developed that will integrate with the health information infrastructure to allow fast, accurate and easy-to-use assays. These can be used in global health and crisis response environments, as well as in clinical settings. Applications in stroke, respiratory disease, cardiac treatment will be featured that will take into consideration the unmet clinical need and the technology development that is unique to each application. The need for generating reliable data and reducing costs will be weighed against other requirements. www.healthtech.com

Advances in molecular diagnostics has enabled the detection of early stage tumors that will lead to greater success rates with intervention and treatment. Tests are being commercialized that employ a variety of approaches utilizing gene expression, serum biomarkers, and circulating tumors cells to capture information early for non-invasive screening of selected populations. Technologies to resolve and isolate the earliest stages of disease can be used in some cases in combination with imaging techniques to differentiate between benign vs. malignant tumors. The potential for these assays to greatly improve patient survival and care is historic and opportune and will further allow the tracking of disease progression. www.healthtech.com

The conference covers all aspects of physical chemistry.

BioPharm America is where biotech industry partnerships get started. Based on the same winning formula used in EBD Group’s distinguished European partnering conferences BIO-Europe and BIO-Europe Spring®, BioPharm America is expected to become the premier stand-alone bio-pharma partnering event in North America. With a clear focus on generating one-to-one meetings for attendees, BioPharm America offers an unrivalled opportunity for participants across the entire biotech value-chain to identify and enter into strategic relationships.

Conference chairs Zheng Yang of Bristol-Myers Squibb and Ellen Q. Wang of Pfizer will present the 3rd annual ACS ProSpectives conference on pharmacokinetics (PK) and pharmacodynamics (PD). This conference is specifically designed for medicinal chemists and team leaders directly involved in the discovery and early development of new drugs who want to learn more about PK-PD and applying it to drug design. The 2-day conference will move from the basic concepts and principles of PK-PD to the application of these concepts to drug discovery programs from various therapeutic areas, including,  Neuroscience  Oncology  Immunology  Metabolic diseases Each session will be highlighted with a case study from the medicinal chemistry perspective that demonstrates the value of understanding PK-PD relationships in the design of better drug molecules.

BioPharm America is where biotech industry partnerships get started. Based on the same winning formula used in EBD Group’s distinguished European partnering conferences BIO-Europe and BIO-Europe Spring®, BioPharm America is expected to become the premier stand-alone bio-pharma partnering event in North America. With a clear focus on generating one-to-one meetings for attendees, BioPharm America offers an unrivalled opportunity for participants across the entire biotech value-chain to identify and enter into strategic relationships.

This conference & exhibition is a major international forum for the discussion of technical aspects of scale-up at the chemistry/chemical engineering interface in the pharmaceutical, fine chemical and allied fields. Topics include: the scale-up of batch and semi-batch processes, continuous processing and reaction engineering, microreactor technology, safety and thermochemistry, scale-up of potentially hazardous chemistry, green chemistry, quality assurance and regulatory concerns, solid form control (crystallisation & polymorphism), separation and purification techniques, and new technologies and equipment for large scale manufacture.

Optimizing Cell Culture Development will include talks from industry experts that address critical issues in an atmosphere that encourages sharing, learning, and networking. The agenda will again feature small-group breakout discussions that will provide the opportunity to discuss important topics with your peers in a fun and collegial setting. In addition, case studies will be presented that shed light on improving yield while maintaining product quality within the regulatory framework. www.healthtech.com

Sought by most international pharmaceutical and biotechnology companies, China has become a partner of choice for international biopharmaceutical companies. In order to minimize unnecessary expenses, time and risk involved in R&D, companies have found an effective solution and worthy partner in this low-cost region populated by a highly-skilled drug discovery and development talent pool. In addition, due to its growing western-educated middle class, China presents valuable commercial opportunities for pharmaceutical and biotechnology companies. www.healthtech.com

The Baculovirus Technology meeting will bring together experts who are achieving breakthroughs and clinical success. Innovative approaches to tackling the problems of increasing protein expression levels and humanizing the N-glycosylation pathway will be addressed, along with case studies from industry leaders. www.healthtech.com